Effective November 1st, the Department of Health can enter into contracts with drug developers to conduct ibogaine clinical trials.
Effective November 1st, the Department of Health can enter into contracts with drug developers to conduct ibogaine clinical trials.
Previously limited to veterans and other specific populations, the bill could apply to any adult that meets clinical eligibility criteria.
Psilocybin and ibogaine clinical trials would target opioid use disorder and treatment-resistant mental health conditions.
A three-year pilot program would allow for 1,000 patients annually to receive treatment for PTSD, depression, chronic pain, and more.
The order seeks to accelerate clinical trials, data sharing, drug approvals, and possibly rescheduling.
Certain members of the Research Advisory Panel of California may conduct expedited reviews and approvals of research applications.
Senate Bill 219 allows for psilocybin therapy for the treatment of PTSD, treatment-resistant depression, and more.
Colorado’s bill allows for prescription of psilocybin upon an FDA-approved product, while North Dakota lists psilocybin as a Schedule IV drug.
Both bills passed their respective House and Senate chambers with the two-thirds majority needed to override a potential veto.
Along with the supervised therapeutic use, the bill would implement a sales tax, public education, and much more.
Hawaii considers partial coverage, Missouri wants stricter guidelines, & Texas proposes a grant program for military and first responders.
Five different states are proposing legislation for psychedelic therapy or legalized use for the treatment of PTSD and other mental illnesses.
Senate Bill 495 seeks to legalize medical psilocybin under strict conditions with state-regulated training, research, reporting, and more.
Medical use would be legalized, with legal protections for patients and physicians.
When injected into the hippocampus, the compound DOI reduced anxiety in mice without causing hallucinations.
